EYPT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -184.82% compared to EyePoint Pharmaceuticals's net margin of -49.65%. EyePoint Pharmaceuticals's return on equity of -55.1% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

EyePoint Pharmaceuticals has a consensus price target of $32.00, signalling upside risk potential of 445.15%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 51.76%. Given that EyePoint Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $24.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. EyePoint Pharmaceuticals's net income of -$45.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 6.34x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -184.82% compared to EyePoint Pharmaceuticals's net margin of -1036.46%. EyePoint Pharmaceuticals's return on equity of -55.1% beat Ocugen's return on equity of -215.5%.

EyePoint Pharmaceuticals has a consensus price target of $32.00, signalling upside risk potential of 445.15%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 683.13%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $24.5M, which are larger than Ocugen quarterly revenues of $1.5M. EyePoint Pharmaceuticals's net income of -$45.2M is lower than Ocugen's net income of -$15.4M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 6.34x versus 51.33x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -184.82% compared to EyePoint Pharmaceuticals's net margin of --. EyePoint Pharmaceuticals's return on equity of -55.1% beat Oragenics's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $32.00, signalling upside risk potential of 445.15%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that EyePoint Pharmaceuticals has higher upside potential than Oragenics, analysts believe EyePoint Pharmaceuticals is more attractive than Oragenics.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $24.5M, which are larger than Oragenics quarterly revenues of --. EyePoint Pharmaceuticals's net income of -$45.2M is lower than Oragenics's net income of -$2.2M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 6.34x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -184.82% compared to EyePoint Pharmaceuticals's net margin of --. EyePoint Pharmaceuticals's return on equity of -55.1% beat Theriva Biologics's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $32.00, signalling upside risk potential of 445.15%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1421.74%. Given that Theriva Biologics has higher upside potential than EyePoint Pharmaceuticals, analysts believe Theriva Biologics is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $24.5M, which are larger than Theriva Biologics quarterly revenues of --. EyePoint Pharmaceuticals's net income of -$45.2M is lower than Theriva Biologics's net income of -$4.3M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 6.34x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.